Mutual of America Capital Management LLC Invests $399,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Mutual of America Capital Management LLC purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 8,860 shares of the company’s stock, valued at approximately $399,000.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Protagonist Therapeutics by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock worth $92,373,000 after buying an additional 39,055 shares during the last quarter. New York State Teachers Retirement System acquired a new stake in shares of Protagonist Therapeutics during the third quarter worth about $1,107,000. Seven Eight Capital LP lifted its holdings in shares of Protagonist Therapeutics by 426.9% in the 2nd quarter. Seven Eight Capital LP now owns 36,793 shares of the company’s stock valued at $1,275,000 after purchasing an additional 29,810 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Protagonist Therapeutics by 9.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 204,299 shares of the company’s stock valued at $7,079,000 after purchasing an additional 17,065 shares during the period. Finally, Dark Forest Capital Management LP purchased a new position in Protagonist Therapeutics during the 2nd quarter worth approximately $2,112,000. 98.63% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Protagonist Therapeutics

In other news, insider Suneel Gupta sold 103,437 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $46.04, for a total value of $4,762,239.48. Following the completion of the transaction, the insider now owns 256,174 shares of the company’s stock, valued at $11,794,250.96. The trade was a 28.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Dinesh V. Ph D. Patel sold 78,520 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $46.96, for a total transaction of $3,687,299.20. Following the completion of the sale, the chief executive officer now directly owns 435,208 shares of the company’s stock, valued at $20,437,367.68. The trade was a 15.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 232,066 shares of company stock valued at $10,681,738 in the last ninety days. Corporate insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Stock Performance

Protagonist Therapeutics stock opened at $44.95 on Thursday. The firm has a market capitalization of $2.68 billion, a price-to-earnings ratio of 16.90 and a beta of 2.17. The stock’s fifty day moving average is $45.24 and its two-hundred day moving average is $39.62. Protagonist Therapeutics, Inc. has a fifty-two week low of $17.13 and a fifty-two week high of $48.89.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. Wedbush reiterated an “outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a research report on Tuesday, November 19th. TD Cowen upgraded shares of Protagonist Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 25th. JMP Securities decreased their price target on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 7th. Finally, StockNews.com raised Protagonist Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Protagonist Therapeutics currently has an average rating of “Buy” and an average price target of $53.57.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.